Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine.

abstract：:The consistently high mortality rates associated with gastrointestinal cancer result in large part from malignancies that progress undetected to an advanced stage of disease when treatment is usually less effective. In response to this fact, increasing attention has been directed toward developing methods of both prim...

journal_title：Seminars in oncology

authors： Winawer SJ

更新日期：1991-02-01 00:00:00

abstract：:Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite the advent of disease-modifying therapies for MDS (eg, azacitidine, decitabine, and lenalidomide) and the current absence of an MDS-specific US Food and Drug Adm...

journal_title：Seminars in oncology

authors： Steensma DP

更新日期：2011-10-01 00:00:00

abstract：:This phase I trial was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin (400 mg/m2) as first-line chemotherapy for stage IIIC/IV ovarian adenocarcinoma. After premedication, paclitaxel was infu...

journal_title：Seminars in oncology

authors： Lhommé C,Kerbrat P,Lejeune C,Guastalla JP,Fumoleau P,Goupil A,Héron JF,Cassin MA,Pruvot I,Soares JA,Chazard M

更新日期：1996-10-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In...

journal_title：Seminars in oncology

authors： Raufi AG,Manji GA,Chabot JA,Bates SE

更新日期：2019-02-01 00:00:00

abstract：:The benefits of radiation therapy (RT) as part of a treatment regimen for cancer must be weighed against the potential risk of harm to the patient and in the pregnant patient, the risk to the developing fetus. Information necessary for determining the potential effects of RT on the developing fetus include the gestati...

journal_title：Seminars in oncology

authors： Greskovich JF Jr,Macklis RM

更新日期：2000-12-01 00:00:00

abstract：:In the last decade our understanding of chronic lymphocytic leukemia (CLL) biology and pathogenesis has increased substantially. These insights have led to the development of several new agents with novel mechanisms of action prompting a change in therapeutic approaches from chemotherapy-based treatments to targeted t...

journal_title：Seminars in oncology

authors： Herman SE,Wiestner A

更新日期：2016-04-01 00:00:00

abstract：:Lymphoproliferative disorders are characterized by the abnormal accumulation of aberrant lymphocytes, which frequently interfere with the processes associated with immunologic response and hematopoiesis. Chronic lymphocytic leukemia (CLL) has traditionally been considered indolent, with a prolonged clinical course. Ho...

journal_title：Seminars in oncology

authors： Hillmen P

更新日期：2006-04-01 00:00:00

abstract：:Organ function preservation in patients with head and neck cancer can be achieved by intensity-modulated radiation therapy (IMRT). Much of the work on the physics of IMRT has been done for currently available IMRT systems. However, clinical data remain scarce. Before IMRT is accepted as a standard of care, more compre...

journal_title：Seminars in oncology

authors： Chao KS,Ozyigit G,Thorsdad WL

更新日期：2003-12-01 00:00:00

abstract：:The sequencing of targeted therapy is well established in metastatic renal cancer. Switching between different vascular endothelial growth factor (VEGF)-targeted therapies or VEGF-targeted therapies and mammalian target of rapamycin (mTOR) inhibitors are both of proven benefit. The optimal sequence remains unclear. Un...

journal_title：Seminars in oncology

authors： Escudier B,Gore M

更新日期：2013-08-01 00:00:00

abstract：:Publicly funded cancer medicines listed on the New Zealand Pharmaceutical Schedule were compared with those listed on the Australian Pharmaceutical Benefits Scheme. To quantify the health gains offered by the cancer medicines funded in Australia but not in New Zealand, clinical trial data reporting median progression-...

journal_title：Seminars in oncology

authors： Evans J,Laking G,Strother M,Wang T,Metcalfe S,Blick G,Pauls R,Crausaz S

更新日期：2016-12-01 00:00:00

abstract：:While cancers of the upper gastrointestinal tract are related by location, they have distinct clinical and molecular characteristics. This review will focus on the molecular biology of esophageal adenocarcinoma (EAC) of which alterations in p53, overexpression of cyclin D1, loss of p16, and aneuploidy have been best c...

journal_title：Seminars in oncology

authors： Lin J,Beerm DG

更新日期：2004-08-01 00:00:00

abstract：:Gemcitabine is a novel nucleoside analogue that has demonstrated activity against several solid tumors. A large phase II study has been performed in Europe and Canada with a total enrollment of 161 non-small cell lung cancer patients, 26 of whom were from the Institut Gustave-Roussy. Patient characteristics were the s...

journal_title：Seminars in oncology

authors： Le Chevalier T,Gottfried M

更新日期：1997-04-01 00:00:00

abstract：:Gastrointestinal stromal tumor (GISTs) are the most common connective tissue malignancies of the gastrointestinal (GI) tract, with an incidence on the order of 10-13 per million people per year. Primary therapy is usually surgical, but the recurrence rate of large, so-called high-risk tumors, with a high mitotic rate,...

journal_title：Seminars in oncology

authors： Reichardt P,Hogendoorn PC,Tamborini E,Loda M,Gronchi A,Poveda A,Schöffski P

更新日期：2009-08-01 00:00:00

abstract：:Although bone and soft tissue sarcomas are not common, a significant number of patients who develop these tumors will die with metastatic disease. Part of the reason is that many of the patients have advanced disease at diagnosis. Identification of an etiologic agent should allow for diagnosis at an earlier stage. Thi...

journal_title：Seminars in oncology

authors： McClay EF

更新日期：1989-08-01 00:00:00

abstract：:As antineoplastic therapy improves, patients with cancer will have the potential for prolonged survival. Tumor products may produce metabolic complications, such as hypercalcemia, hyponatremia, and hypoglycemia, and these conditions must be promptly recognized so that treatment can be initiated before severe or life-t...

journal_title：Seminars in oncology

authors： Silverman P,Distelhorst CW

更新日期：1989-12-01 00:00:00

abstract：:A large meta-analysis showed that chemotherapy results in significant prolongation of survival for patients with non-small cell lung cancer (NSCLC). Pemetrexed is a new multitargeted antifolate chemotherapeutic agent that has shown activity in NSCLC and appears to be similar to the third-generation antitumor agents cu...

journal_title：Seminars in oncology

authors： Shepherd FA

更新日期：2002-12-01 00:00:00

abstract：:The heat-shock proteins (HSPs) belong to a family of ubiquitous and abundant proteins used successfully in prophylactic and therapeutic vaccination against tumors. The HSPs are natural chaperones of peptides that reflect the immunologic composition of the cell. Immunization with tumor-derived HSP-peptide complexes (HS...

journal_title：Seminars in oncology

authors： Ménoret A,Chandawarkar R

更新日期：1998-12-01 00:00:00

abstract：:The current oncology practice of treating cancer with aggressive doses of radiation and chemotherapy is potentially disastrous, as response and side effects vary depending on several factors including pharmacogenetics. This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and ...

journal_title：Seminars in oncology

authors： Wu X,Lu C,Chiang SS,Ajani JA

更新日期：2005-12-01 00:00:00

abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

journal_title：Seminars in oncology

authors： Cella D

更新日期：2004-12-01 00:00:00

abstract：:Myeloid neoplasms are characterized by acquired somatic mutations and epigenetic alterations in genes that are crucial for hematopoietic differentiation and cellular proliferation and survival pathways. The heterogeneity and genetic complexity of these disorders is daunting, but the improvement in our knowledge of the...

journal_title：Seminars in oncology

authors： Odenike O,Thirman MJ,Artz AS,Godley LA,Larson RA,Stock W

更新日期：2011-04-01 00:00:00

abstract：:Pancreatic cancer is the eighth most common cancer in Europe, accounting for 4.1% of cancer deaths in men and 4.8% in women. Standardized pancreatoduodenectomy and left pancreatectomy are the gold standard for routine surgical treatment of pancreatic cancer. Total pancreatectomy should be reserved for positive pancrea...

journal_title：Seminars in oncology

authors： Pedrazzoli S,Pasquali C,Sperti C

更新日期：2002-12-01 00:00:00

abstract：:In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung ca...

journal_title：Seminars in oncology

authors： Pisters KM,Kris MG,Bunn PA Jr,Johnson DH,Ruckdeschel JC,Crowley JJ,Ginsberg RJ

更新日期：1997-08-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) displays nonlinear pharmacokinetics in humans. Both peak plasma paclitaxel concentrations and areas under the curve (AUCs) of the concentration versus time profiles will change disproportionately to changes in dose. Models that accurately describe the pla...

journal_title：Seminars in oncology

authors： Kearns CM,Gianni L,Egorin MJ

更新日期：1995-06-01 00:00:00

abstract：:In vitro uptake and retention of 3H-cytosine arabinoside (ara-C) was studied in 68 acute myelogenous leukemia (AML) patients (ten were studied twice) treated with a regimen containing conventional (54 patients) or high doses (24) of ara-C. Drug uptake and retention after four hours were measured following 30 minutes e...

journal_title：Seminars in oncology

authors： Zittoun R,Marie JP,Delanian S,Suberville AM,Thevenin D

更新日期：1987-06-01 00:00:00

abstract：:To address the urgent need for novel therapies for multiple myeloma (MM), long-term research efforts have characterized the mechanisms whereby MM cells home to the bone marrow and adhere to bone marrow stromal cells and extracellular matrix proteins. Research also characterizes the functional sequelae of this binding ...

journal_title：Seminars in oncology

authors： Anderson KC

更新日期：2002-12-01 00:00:00

abstract：:Eighteen percent of incident malignancies in the United States are a second (or subsequent) cancer. Second primary neoplasms (SPNs), particularly solid tumors, are a major cause of mortality and serious morbidity among cancer survivors successfully cured of their first cancer. Multiple etiologies may lead to a cancer ...

journal_title：Seminars in oncology

authors： Oeffinger KC,Baxi SS,Novetsky Friedman D,Moskowitz CS

更新日期：2013-12-01 00:00:00

abstract：:Most cellular proto-oncogenes encode proteins that participate in signaling pathways by which cells receive and execute instructions that lead to mitogenesis, differentiation, lineage determination, cell migration, extracellular matrix production, and apoptosis, among others. These proto-oncogene protein products incl...

journal_title：Seminars in oncology

authors： Arteaga CL,Khuri F,Krystal G,Sebti S

更新日期：2002-02-01 00:00:00

abstract：:In April 1990, the Argentine Group for Treatment of Acute Leukemia began a multicenter trial for the treatment of previously untreated acute myeloblastic leukemia patients who were under 21 years of age. Initial treatment consisted of an 8-day induction phase with cytarabine together with idarubicin on days 3 to 5 and...

journal_title：Seminars in oncology

authors： Sackmann-Muriel F,Fernández-Barbieri MA,Santarelli MT,Matus-Ridley M,Rosso A,Negri-Aranguren P,Cerutti I,Gomel M,Kvicala R

更新日期：1993-12-01 00:00:00

abstract：:Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term su...

journal_title：Seminars in oncology

authors： Laport GF,Williams SF

更新日期：1998-08-01 00:00:00

abstract：:Patients diagnosed with germ cell tumors (GCT) are relatively young, and most are rendered disease-free by primary treatment. Also, second-line therapies in nearly all instances are potentially curative. Therefore, the schedule and modalities of follow-up testing are important issues in detecting recurrence of GCT and...

journal_title：Seminars in oncology

authors： Kondagunta GV,Sheinfeld J,Motzer RJ

更新日期：2003-06-01 00:00:00